# Decheng Capital

> Decheng Capital is a life sciences investment firm founded in 2012 by Min Cui. It provides capital and strategic support to early-stage life science companies and growth-stage healthcare businesses, with more than $2.5 billion in self-reported assets under management and offices in Menlo Park and Shanghai.

- **Founded:** 2012
- **Headquarters:** Menlo Park, United States
- **Founders:** Min Cui (Founder and Managing Director)
- **Products:** Early-stage life sciences investing, Growth-stage healthcare investing, Board and strategic support
- **Notable:** Self-reports more than $2.5 billion in assets under management., Led Cellares’ $82 million Series B in 2021, with Eclipse as co-lead., Portfolio company Alpine Immune Sciences was the subject of Vertex’s approximately $4.9 billion acquisition agreement in April 2024.

## Products & services

- **Early-stage life sciences investing** — Equity capital and company-building support for scientific entrepreneurs, including biotech, diagnostics and life science tools.
- **Growth-stage healthcare investing** — Investment in healthcare businesses with established market presence, including medical technology and services.
- **Board and strategic support** — Portfolio-company governance and strategic involvement; Min Cui publicly lists current and former board appointments.

## Achievements

- Self-reports more than $2.5 billion in assets under management.
- Led Cellares’ $82 million Series B in 2021, with Eclipse as co-lead.
- Portfolio company Alpine Immune Sciences was the subject of Vertex’s approximately $4.9 billion acquisition agreement in April 2024.
- Portfolio includes CG Oncology, which completed an IPO in 2024.

## Latest updates

- **2026-06** — Portfolio company Cellares expanded its Series D to $327 million after a $50 million Prime Radiant Partners investment; this does not establish Decheng’s participation in that extension.
- **2026-01** — Cellares announced a $257 million Series D co-led by BlackRock-managed funds and Eclipse.
- **2025-10** — Fund V amended its SEC Form D, reporting $452 million sold and 42 investors.

## Links

- Website: https://www.decheng.com/
- LinkedIn: https://www.linkedin.com/company/decheng-capital-

---

Profile page: https://yespress.io/decheng-capital
Published by YesPress — https://yespress.io
Last updated: 2026-10-27